Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
trastuzumab
trastuzumab
- Restricted
- Restricted Herceptin, Herzuma, Kanjinti, Ogivri, Trazimera, Ontruzant --> restricted to outpatient oncology.
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Ontruzant | POWDER FOR INJECTION, INTRAVENOUS | 150 mg | ||||
| Herzuma | POWDER FOR INJECTION, INTRAVENOUS | 420 mg | ||||
| Kanjinti | POWDER FOR INJECTION, INTRAVENOUS | 420 mg | ||||
| Ogivri | POWDER FOR INJECTION, INTRAVENOUS | 420 mg | ||||
| Trazimera | POWDER FOR INJECTION, INTRAVENOUS | 420 mg | ||||
| Herceptin | POWDER FOR INJECTION, INTRAVENOUS | 440 mg |
Last updated: Mar. 19, 2024
- Black Box Warning: Cardiomyopathy; infusion reactions, pulmonary toxicity; teratogenicity
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
TRASTUZUMAB (original brand name Herceptin)
Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera are biosimilars to Herceptin, whichever product is more financially advantageous to the patient and institution will be dispensed for a specific case or during a certain time period.
Interchange ratio of 1 mg to 1 mg.
Reviewed: 24 April 2018 (Ogivri), and 23 April 2019 (Herzuma), 24 Sept 2019 (Kanjinti and Trazimera). 28 January 2020 (Ontruzant)